• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

同侧同步性乳头状和透明细胞肾细胞癌:1例报告并文献复习

Ipsilateral synchronous papillary and clear renal cell carcinoma: A case report and review of literature.

作者信息

Yin Jing, Zheng Mo

机构信息

Department of Pathology, The Fifth Central Hospital of Tianjin, Binhai New Area, Tianjin 300450, China.

出版信息

World J Clin Cases. 2022 Jun 6;10(16):5428-5434. doi: 10.12998/wjcc.v10.i16.5428.

DOI:10.12998/wjcc.v10.i16.5428
PMID:35812682
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9210906/
Abstract

BACKGROUND

There is limited information on ipsilateral synchronous papillary renal cell carcinoma (PRCC) and clear cell renal cell carcinoma (CCRCC). Therefore, these rare tumors are often misdiagnosed preoperatively as a single tumor with intrarenal metastasis or some other diseases. Effective management and long-term overall survival might be affected because the prognosis of the two tumors differs.

CASE SUMMARY

We describe a case of ipsilateral synchronous PRCC and CCRCC with two histological variants in a 72-year-old man, whose mass was found incidentally, with no other chief complaints and vital signs were normal. Initial ultrasound revealed a hypoechoic lobular mass with a volume of 7.8 cm × 4.8 cm × 2.8 cm in the middle to lower pole of the left kidney. A subsequent contrast-enhanced computed tomography scan showed a single endophytic mass of 7.5 cm in diameter. The patient underwent laparoscopic left radical nephrectomy. A final diagnosis of ipsilateral synchronous PRCC and CCRCC was confirmed by pathological examination. There was no recurrence or metastasis after 25 mo follow-up.

CONCLUSION

We report a case of ipsilateral synchronous PRCC and CCRCC, and review related literature to estimate the prevalence of similar cases. The above descriptions may be expected to help understand the disease, and improve diagnosis in the future.

摘要

背景

关于同侧同步性乳头状肾细胞癌(PRCC)和透明细胞肾细胞癌(CCRCC)的信息有限。因此,这些罕见肿瘤术前常被误诊为单一肿瘤伴肾内转移或其他疾病。由于这两种肿瘤的预后不同,可能会影响有效的治疗和长期总生存期。

病例摘要

我们描述了一例72岁男性同侧同步性PRCC和CCRCC病例,该患者有两种组织学变体,肿块为偶然发现,无其他主要主诉,生命体征正常。最初的超声检查显示左肾中下级有一个低回声小叶肿块,体积为7.8 cm×4.8 cm×2.8 cm。随后的增强计算机断层扫描显示一个直径7.5 cm的单发内生性肿块。患者接受了腹腔镜下左肾根治性切除术。病理检查确诊为同侧同步性PRCC和CCRCC。随访25个月后无复发或转移。

结论

我们报告了一例同侧同步性PRCC和CCRCC病例,并回顾相关文献以评估类似病例的发生率。上述描述可能有助于了解该疾病,并在未来改善诊断。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64ff/9210906/30ced239e36c/WJCC-10-5428-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64ff/9210906/907f8ad45f91/WJCC-10-5428-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64ff/9210906/30ced239e36c/WJCC-10-5428-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64ff/9210906/907f8ad45f91/WJCC-10-5428-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64ff/9210906/30ced239e36c/WJCC-10-5428-g002.jpg

相似文献

1
Ipsilateral synchronous papillary and clear renal cell carcinoma: A case report and review of literature.同侧同步性乳头状和透明细胞肾细胞癌:1例报告并文献复习
World J Clin Cases. 2022 Jun 6;10(16):5428-5434. doi: 10.12998/wjcc.v10.i16.5428.
2
Histologic subtype needs to be considered after partial nephrectomy in patients with pathologic T1a renal cell carcinoma: papillary vs. clear cell renal cell carcinoma.对于病理分期为T1a期的肾细胞癌患者,行部分肾切除术后需要考虑组织学亚型:乳头状肾细胞癌与透明细胞肾细胞癌。
J Cancer Res Clin Oncol. 2017 Sep;143(9):1845-1851. doi: 10.1007/s00432-017-2430-6. Epub 2017 Apr 27.
3
Tumor-to-tumor metastases: papillary thyroid carcinoma into a clear cell renal cell carcinoma.肿瘤至肿瘤转移:甲状腺乳头状癌转移至肾透明细胞癌
J Otolaryngol Head Neck Surg. 2017 Mar 1;46(1):17. doi: 10.1186/s40463-017-0193-3.
4
Clinicopathological Features of Papillary Renal Cell Carcinoma With Venous Tumor Thrombus: Case Series from a Large Chinese Center.伴静脉瘤栓的乳头状肾细胞癌的临床病理特征:来自中国大型中心的病例系列
Clin Med Insights Oncol. 2022 Apr 17;16:11795549221092217. doi: 10.1177/11795549221092217. eCollection 2022.
5
Papillary renal cell carcinoma and clear cell renal cell carcinoma: Differentiation of distinct histological types with contrast - enhanced ultrasonography.乳头状肾细胞癌和透明细胞肾细胞癌:用超声造影鉴别不同组织学类型。
Eur J Radiol. 2015 Oct;84(10):1849-56. doi: 10.1016/j.ejrad.2015.06.017. Epub 2015 Jun 25.
6
Diagnostic and prognostic tissuemarkers in clear cell and papillary renal cell carcinoma.透明细胞和乳头状肾细胞癌的诊断和预后组织标志物。
Cancer Biomark. 2010;7(6):261-8. doi: 10.3233/CBM-2010-0195.
7
Tumor grade estımatıon of clear cell and papıllary renal cell carcınomas usıng contrast-enhanced MDCT and FSE T2 weıghted MR ımagıng: radıology-pathology correlatıon.利用对比增强MDCT和FSE T2加权MRI图像对透明细胞和乳头状肾细胞癌进行肿瘤分级评估:放射学与病理学相关性研究
Radiol Med. 2021 Sep;126(9):1139-1148. doi: 10.1007/s11547-021-01350-y. Epub 2021 Jun 7.
8
Cytology diagnosis of metastatic clear cell renal cell carcinoma, synchronous to pancreas, and metachronous to thyroid and contralateral adrenal: Report of a case and literature review.胰腺同步、甲状腺及对侧肾上腺异时转移的透明细胞肾细胞癌的细胞学诊断:1例报告及文献复习
Diagn Cytopathol. 2017 Feb;45(2):161-167. doi: 10.1002/dc.23619. Epub 2016 Oct 22.
9
Whole lesion quantitative CT evaluation of renal cell carcinoma: differentiation of clear cell from papillary renal cell carcinoma.肾细胞癌的全病灶定量CT评估:透明细胞肾细胞癌与乳头状肾细胞癌的鉴别
Springerplus. 2015 Feb 10;4:66. doi: 10.1186/s40064-015-0823-z. eCollection 2015.
10
Ipsilateral synchronous clear and papillary renal cell carcinoma: A case report and review of the literature.同侧同步透明细胞型和乳头状肾细胞癌:一例报告并文献复习
Urol Case Rep. 2017 Nov 23;16:110-113. doi: 10.1016/j.eucr.2017.11.020. eCollection 2018 Jan.

引用本文的文献

1
Occurrence of papillary renal cell carcinoma and clear cell renal carcinoma in a patient: A unique case report.一名患者同时发生乳头状肾细胞癌和透明细胞肾细胞癌:一例独特病例报告。
Medicine (Baltimore). 2025 May 2;104(18):e42312. doi: 10.1097/MD.0000000000042312.
2
N-methyladenosine (mA) reader IGF2BP1 facilitates clear-cell renal cell carcinoma aerobic glycolysis.N6-甲基腺苷(mA)读码器 IGF2BP1 促进肾透明细胞癌的有氧糖酵解。
PeerJ. 2023 Jan 18;11:e14591. doi: 10.7717/peerj.14591. eCollection 2023.

本文引用的文献

1
How to improve outcome in nephron-sparing surgery: the impact of new techniques.如何提高保肾手术的疗效:新技术的影响。
Curr Opin Urol. 2021 May 1;31(3):255-261. doi: 10.1097/MOU.0000000000000862.
2
Kidney Cancer: An Overview of Current Therapeutic Approaches.肾癌:当前治疗方法概述。
Urol Clin North Am. 2020 Nov;47(4):419-431. doi: 10.1016/j.ucl.2020.07.009.
3
Neoadjuvant Cabozantinib in Renal-Cell Carcinoma: A Brief Review.新辅助卡博替尼治疗肾细胞癌:简要综述。
Clin Genitourin Cancer. 2020 Dec;18(6):e688-e691. doi: 10.1016/j.clgc.2020.04.003. Epub 2020 Apr 21.
4
Adjuvant therapy in renal cell carcinoma.肾细胞癌的辅助治疗。
Cancer. 2019 Sep 1;125(17):2935-2944. doi: 10.1002/cncr.32144. Epub 2019 Jun 21.
5
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018:GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
6
A Multicenter Phase II Trial of Axitinib in Patients With Recurrent or Metastatic Non-clear-cell Renal Cell Carcinoma Who Had Failed Prior Treatment With Temsirolimus.阿昔替尼治疗既往接受替西罗莫司治疗失败的复发性或转移性非透明细胞肾细胞癌患者的多中心 II 期临床试验。
Clin Genitourin Cancer. 2018 Oct;16(5):e997-e1002. doi: 10.1016/j.clgc.2018.05.011. Epub 2018 May 23.
7
Second-Line Treatment Landscape for Renal Cell Carcinoma: A Comprehensive Review.二线治疗肾癌全景:全面综述。
Oncologist. 2018 May;23(5):540-555. doi: 10.1634/theoncologist.2017-0534. Epub 2018 Feb 27.
8
Evolving Treatment Paradigms in Non-clear Cell Kidney Cancer.非透明细胞肾癌的治疗模式演变。
Curr Treat Options Oncol. 2018 Jan 24;19(1):5. doi: 10.1007/s11864-018-0521-5.
9
Ipsilateral synchronous clear and papillary renal cell carcinoma: A case report and review of the literature.同侧同步透明细胞型和乳头状肾细胞癌:一例报告并文献复习
Urol Case Rep. 2017 Nov 23;16:110-113. doi: 10.1016/j.eucr.2017.11.020. eCollection 2018 Jan.
10
Targeted therapies for renal cell carcinoma.肾细胞癌的靶向治疗。
Nat Rev Nephrol. 2017 Aug;13(8):496-511. doi: 10.1038/nrneph.2017.82. Epub 2017 Jul 10.